Q1 2023

Filed May 12, 2023 · 10-Q · 42 days after period end · 0000950170-23-021755

Q1 2023 · 10-Q

Revenue—

Net Income

-$19.61M

N/M vs Q1 2022

EPS Diluted

-$72.20

N/M vs Q1 2022

Operating Income-$20,086,000N/M

Operating Cash Flow-$19,689,000N/M

Same quarter

Metric	Q1 2023	Q1 2022	Q1 2021	Q1 2020
Revenue	—	$0.00	$4.65M	$7.26M
Net Income	-$19.61M	-$23.39M	-$20.38M	-$4.91M
EPS Diluted	-$72.20	-$0.67	-$0.60	-$0.16

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR